Objective: To evaluate long-term outcomes of 60 extremely low birth weight (ELBW) infants treated with or without three injections of high-dose erythropoietin (Epo).
Introduction
A safe intervention is needed that can provide neuroprotection for neonates at risk for brain injury and neurodevelopmental impairment (NDI) due to complications of birth and prematurity. At present, cerebral palsy (CP) is present in 10 to 15% of all preterm survivors. 1 For the extremely preterm (born <26 weeks gestation), 50% exhibit mild to severe NDI at 30 months of age, 2 and NDI prevalence increases to 80% by the age of 6 years. 3 Erythropoietin (Epo) is a promising neuroprotective therapy being considered for such high risk neonates. 4 Epo has anti-apoptotic 5, 6 and anti-inflammatory effects, 7, 8 and it also increases neurogenesis [9] [10] [11] and protects oligodendrocytes. [12] [13] [14] These effects may counteract injury and improve neurodevelopmental outcomes in vulnerable preterm infants. Pragmatically, Epo is also attractive because it is widely available, affordable and safe for promoting erythropoiesis in preterm infants.
We previously completed a prospective, dose-escalation, openlabel phase I/II study of high-dose Epo given to 30 extremely low birth weight (ELBW) infants to determine pharmacokinetics and short-term safety. Short-term outcomes were compared with 30 concurrent controls. 15 We now report the long-term outcomes of these infants. This report contains the only available long-term outcome data for ELBW infants treated with early high-dose Epo.
Methods

Overview
We conducted a retrospective analysis of all available follow-up data from subjects previously enrolled in the parent study described below. Prior approval was obtained from the institutional review board at the University of Washington (Seattle, WA, USA). Developmental assessments were performed at the high-risk infant follow-up clinic and archived data were collected from paper charts and the electronic medical database (Mindscape).
Parent study
The parent study 15 was a prospective, dose-escalation, open-label phase I/II evaluation of the acute safety and pharmacokinetics of early high-dose Epo treatment given to ELBW infants born <1000 g and p28 to 6/7 weeks gestational age. Sixty subjects were enrolled from January 2006 through March 2007. Thirty concurrent controls were compared with 30 Epo-treated subjects. Epo-treated subjects, but not untreated controls, had blood samples drawn for detection of plasma Epo pharmacokinetics. Early Epo treatment involved daily intravenous Epo injections for the first 3 days of age. Three doses of recombinant human Epo (500, 1000 or 2500 U/kg) were administered in the parent study (n ¼ 10 per dose). After the early treatment period, late Epo treatment for anemia of prematurity was available to any infant (including control) at the discretion of the attending physician. The parent study was registered with the US Food and Drug Administration (IND 12656), and results were reported in Pediatrics.
15
Follow-up Participation in the follow-up program was voluntary. All assessments were conducted from August 2006 to June 2010 by certified examiners who were blind to prior treatment status. Evaluations included a standardized neurologic examination, anthropometrics (height, weight and head circumference) and determination of motor and cognitive performance using the Bayley Scales of Infant Development 2nd Edition (BSID-II) and Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III). BSID-II MDI (mental developmental scores) scores were transformed to BSID-III cognitive scores using the recently published conversion formula 0.59 Â MDI þ 52. 16 Developmental delay was defined as a cognitive or motor score <85 (1 s.d. below mean) or when severity of impairment prohibited testing. The severity of NDI was assessed for all infants that survived up to 12 months corrected age and was defined as moderate if any cognitive or motor score was p85, or severe if any score was p70 or if the diagnosis of CP, blindness or deafness was made. Hearing status was determined from parental reports and supplemented with the results of available audiologic examinations. Deafness was defined as disability that required amplification. Vision status was determined from a standard eye examination (tracking, nystagmus and roving eye movement), interviews, prior ophthalmologic examinations and assessment of electronic hospital records. Blindness was defined as a corrected visual acuity <20/200. Final evaluations of retinopathy of prematurity were made at the 12-month follow-up visit based on the international classification. 17 Statistics Data were analyzed using the SPSS software (SPSS, Chicago, IL, USA). w 2 test was chosen to compare proportional data. Mixedmodel analysis of variance (using within-and between-group factors) or multiple linear regression for main effects was performed to identify factors associated with neurodevelopmental scores. Both the standardized correlation coefficient (R) and the unstandardized regression coefficient B (which indicates the magnitude of the score change due to each factor) are presented. 18 All comparisons were two-tailed, with ap0.05. Some data are presented as means with s.e.m. or s.d. Owing to the limited number of available scores, data from infants given different early Epo doses are collectively evaluated as Epo-treated in the current analysis.
Results
In the parent study, 30 untreated control and 30 Epo-treated ELBW infants were enrolled, and 51 infants survived up to discharge (26 control and 25 Epo-treated). Neonatal survival was not affected by treatment, 15 and no additional deaths occurred after discharge.
Including mortalities, follow-up outcomes were identified for 49/60 infants (82%). Thirty-nine of the 51 surviving subjects were examined at least once in the high-risk follow-up clinic. When testing began in August 2006, tests were exclusively BSID-II. After April 2007, BSID-III tests became available. There were 35 infants evaluated with BSID-II and/or BSID-III tests: 16 infants (eight control, eight Epotreated) were exclusively evaluated with BSID-II tests. Nine infants (four control, five Epo-treated) were exclusively evaluated with BSID-III tests, and ten infants (six control, four Epo-treated) were evaluated at early ages with BSID-II tests and then at later ages with BSID-III tests. For combined analysis, all BSID-II MDI scores were transformed into BSID-III cognitive scores using a published formula calculated by correlating BSID-II MDI with BSID-III cognitive scores in both term and preterm infants. 16 Table 1  compares the group birth characteristics and Table 2 compares the group cognitive, motor and language scores for the 35 infants who underwent developmental testing from 4 to 36 months post menstrual age (PMA).
For all subsequent analyses, cognitive scores at 4 months post menstrual age were excluded because they rely heavily on motor response and thus can overestimate early cognitive function. Next, linear regression modeling was performed to correlate neurodevelopmental scores with factors including Epo treatment, gestational age at birth and intraventricular hemorrhage (IVH). Table 3 lists the correlations (R), unstandardized regression coefficients (B) and corresponding P-values for each of these factors. As shown, Epo treatment and gestational age at birth had positive associations, whereas IVH was negatively associated with outcomes. Notably, high-dose Epo was associated with a 5.3 point increase in cognitive score and a 7.5 point increase in motor score.
To evaluate the severity of NDI in each group, we combined neuropathologic diagnoses (blindness, deafness and the diagnosis of CP) with the prevalence of low cognitive or motor scores, using scores of 85 and 70 (1 and 2 s.d. below the mean, respectively). Table 4 list the proportions of low cognitive and motor scores along with the combined NDI severity score. The largest proportion of control infants exhibited severe NDI, and an equally large proportion of Epo-treated infants were only moderately impaired. We considered whether severe NDI was associated with any grade of IVH. 19 In the parent study, seven infants were diagnosed with IVH (confirmed by early and late cranial ultrasound), all seven survived, and six infants participated in the follow-up. Two Epotreated infants had grade 3 IVH and NDI scores of moderate and severe. Four control infants had grades 1, 2, 4 and 4 IVH, and their respective NDI scores were moderate, severe, severe and severe, respectively. Table 4 shows that low motor scores were the predominant source of NDI for both groups of infants.
Typically, baseline plasma Epo concentrations are below detection levels (0.6 mU/ml) in neonates; however, high baseline values (>50 mU/ml) may indicate that hypoxemia was present before birth. 20 We found that five of the Epo-treated infants for whom follow-up data were available had high baseline plasma Epo concentrations. The mean (±s.d.) plasma Epo concentration for the five high-baseline infants was 204 ± 77 mU/ml (range 112 to 322) compared with 6±10 mU/ml (range 0 to 33) for the other 12 low-baseline infants. There was no difference in the proportion of infants with moderate/severe NDI for infants with high baseline Epo (80% with NDI) compared with low baseline Epo infants (82% with NDI). In addition, baseline Epo was not associated with the incidence of severe retinopathy of prematurity (stage 3 or greater). Finally, 8/17 (47%) Epo-treated infants were also treated with late Epo for anemia of prematurity, as were 9/19 (47%) control infants. There was no difference in the proportion of infants with moderate/ severe NDI for infants who received late Epo treatment for anemia of prematurity (70% with NDI) compared with those without exposure to late Epo (84% with NDI).
Anthropometric data (length and occipital-frontal circumference) and daily weights were available from 96% (25/26) of control and 100% (25/25) of Epo-treated patients. There were no effects of Epo on any of these growth indices (data not shown).
Discussion
The most notable findings are that high-dose Epo treatment positively correlated with both cognitive and motor scores, and Epo treatment did not increase adverse long-term outcomes in infants. This report contains the only long-term outcome data from ELBW infants exposed to early high-dose Epo, and these data help address concerns about the long-term safety of early Epo exposure.
The principal limitations of this study are its retrospective nature and the small sample size. Fortunately, the data were balanced with near equal numbers of control and Epo-treated infants. A very recent report correlated preterm BSID-II MDI with BSID-III cognitive scores to calculate the conversion formula 16 that enabled us to compare all the neurodevelopmental scores. Nevertheless, the identified associations should be considered preliminary until a prospective long-term study is conducted using more uniform developmental testing and ensuring more complete follow-up participation. In the parent study, a standardized neurologic assessment of CP was not performed, and thus the prevalence of CP is not known. In addition, data on maternal A clear finding from the current analysis is that Epo treatment was not associated with adverse long-term effects. The parent study examined Epo pharmacokinetics and observed that early high-dose Epo was acutely safe as it did not increase risks for neonatal retinopathy of prematurity, hypertension, polycythemia or seizures. 15 This is consistent with findings from a complementary trial of Epo given to preterm infants (24 to <32 weeks gestation), which also found no increase in short-term risks. 21 These new long-term follow-up data complement those observations. Clinical data that address possible neuroprotective benefits of early Epo treatment are beginning to accumulate. Although doses below 200 U/kg provide no neuroprotective benefit, 22 erythropoietic dosing of ELBW infants using 400 U/kg Epo (x3/week) until 35 weeks corrected age are associated with improved MDI scores. [23] [24] Similarly, in LBW preterm infants treated with Epo (250 to 400 U/kg Â 3/week Â 6 weeks) to prevent anemia of prematurity, MDI scores correlate with cumulative Epo exposure. 25 Also, ELBW neonates treated for anemia of prematurity at birth (250 to 500 U/kg Epo) and evaluated at 10 years of age were more likely to exhibit normal development (55% vs 39%) and their intelligence quotient scores were higher (90.8 vs 81.3) when compared with untreated controls. 26 In a prospective trial of repeated Epo (300 to 500 U/kg Q48 h x14 days), NDI was decreased in term infants with moderate to severe neonatal encephalopathy. 27 In another prospective study of term infants with neonatal encephalopathy, daily Epo treatment (2500 U/kg Â 5 days) acutely decreased serum nitric oxide concentrations and reduced neurologic and developmental abnormalities at 6 months of age. 28 Despite these encouraging findings, the most suitable Epo dosing strategy for effective neuroprotection in preterm neonates is still undetermined. Therefore, a large randomized controlled trial is needed to determine the neuroprotective efficacy of high-dose Epo for either term infants with neonatal encephalopathy or ELBW infants at high risk for NDI. Abbreviations: B, unstandardized regression coefficient; Epo, erythropoietin; GA, gestational age; IVH, intraventricular hemorrhage; R, correlation coefficient. The correlation coefficient (R) and unstandardized regression coefficient (B indicates the score change due to each factor) and corresponding P-value are shown. 
